TrialThe Lancet. Oncology2022

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.

Sacha J Howell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.